KR102409250B1 - 인자 viii 키메라 단백질 및 이들의 용도 - Google Patents

인자 viii 키메라 단백질 및 이들의 용도 Download PDF

Info

Publication number
KR102409250B1
KR102409250B1 KR1020167021744A KR20167021744A KR102409250B1 KR 102409250 B1 KR102409250 B1 KR 102409250B1 KR 1020167021744 A KR1020167021744 A KR 1020167021744A KR 20167021744 A KR20167021744 A KR 20167021744A KR 102409250 B1 KR102409250 B1 KR 102409250B1
Authority
KR
South Korea
Prior art keywords
fviii
seq
delete delete
protein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167021744A
Other languages
English (en)
Korean (ko)
Other versions
KR20160103136A (ko
Inventor
엑타 세스 체브라
통야오 류
Original Assignee
바이오버라티브 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53524349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102409250(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이오버라티브 테라퓨틱스 인크. filed Critical 바이오버라티브 테라퓨틱스 인크.
Publication of KR20160103136A publication Critical patent/KR20160103136A/ko
Application granted granted Critical
Publication of KR102409250B1 publication Critical patent/KR102409250B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020167021744A 2014-01-10 2015-01-09 인자 viii 키메라 단백질 및 이들의 용도 Active KR102409250B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461926226P 2014-01-10 2014-01-10
US61/926,226 2014-01-10
US201461988104P 2014-05-02 2014-05-02
US61/988,104 2014-05-02
PCT/US2015/010738 WO2015106052A1 (en) 2014-01-10 2015-01-09 Factor viii chimeric proteins and uses thereof

Publications (2)

Publication Number Publication Date
KR20160103136A KR20160103136A (ko) 2016-08-31
KR102409250B1 true KR102409250B1 (ko) 2022-06-14

Family

ID=53524349

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167021744A Active KR102409250B1 (ko) 2014-01-10 2015-01-09 인자 viii 키메라 단백질 및 이들의 용도

Country Status (29)

Country Link
US (3) US11192936B2 (cg-RX-API-DMAC7.html)
EP (3) EP3091997B1 (cg-RX-API-DMAC7.html)
JP (5) JP6749836B2 (cg-RX-API-DMAC7.html)
KR (1) KR102409250B1 (cg-RX-API-DMAC7.html)
CN (6) CN116621991A (cg-RX-API-DMAC7.html)
AU (3) AU2015204646B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016015512B1 (cg-RX-API-DMAC7.html)
DK (2) DK3091997T5 (cg-RX-API-DMAC7.html)
EA (1) EA201691111A1 (cg-RX-API-DMAC7.html)
ES (2) ES2927475T3 (cg-RX-API-DMAC7.html)
FI (2) FI4176894T3 (cg-RX-API-DMAC7.html)
FR (1) FR24C1052I1 (cg-RX-API-DMAC7.html)
HR (2) HRP20220960T1 (cg-RX-API-DMAC7.html)
HU (3) HUE066567T2 (cg-RX-API-DMAC7.html)
IL (2) IL246476B (cg-RX-API-DMAC7.html)
LT (3) LT3091997T (cg-RX-API-DMAC7.html)
MX (2) MX389878B (cg-RX-API-DMAC7.html)
MY (2) MY204756A (cg-RX-API-DMAC7.html)
NL (1) NL301303I2 (cg-RX-API-DMAC7.html)
NO (1) NO2024057I1 (cg-RX-API-DMAC7.html)
NZ (1) NZ721544A (cg-RX-API-DMAC7.html)
PH (1) PH12016501323B1 (cg-RX-API-DMAC7.html)
PL (2) PL3091997T3 (cg-RX-API-DMAC7.html)
PT (2) PT3091997T (cg-RX-API-DMAC7.html)
RS (2) RS65533B1 (cg-RX-API-DMAC7.html)
SG (3) SG11201605242YA (cg-RX-API-DMAC7.html)
SI (2) SI3091997T1 (cg-RX-API-DMAC7.html)
UA (1) UA120917C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015106052A1 (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3178835T3 (da) * 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
CN102741422B (zh) 2009-08-24 2016-06-08 阿穆尼克斯运营公司 凝血因子ⅶ组合物及其制备和使用方法
EP2804623B1 (en) * 2012-01-12 2019-08-07 Bioverativ Therapeutics Inc. Chimeric factor viii polypeptides and uses thereof
JP6383666B2 (ja) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド 組換え第ｖｉｉｉ因子タンパク質
EP2814840B1 (en) 2012-02-15 2019-11-13 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
SG10201701037WA (en) * 2012-07-11 2017-03-30 Amunix Operating Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
SI2956477T2 (sl) 2013-02-15 2024-05-31 Bioverativ Therapeutics Inc. Optimiran gen dejavnika VIII
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
HK1223302A1 (zh) * 2013-06-28 2017-07-28 Bioverativ Therapeutics Inc. 具有xten的凝血酶可裂解连接子和其用途
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
HRP20220960T1 (hr) * 2014-01-10 2022-10-28 Bioverativ Therapeutics Inc. Kimerni proteini faktora viii i njihova upotreba
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
EP3297656B1 (en) * 2015-05-22 2020-01-08 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
WO2017024060A1 (en) 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same
WO2017050820A1 (en) * 2015-09-22 2017-03-30 Novo Nordisk A/S Fviii fusion proteins
CN105567733B (zh) * 2016-01-11 2019-04-23 佛山安普泽生物医药股份有限公司 CHO细胞表达凝血酶-Fc融合蛋白的方法
JP7096458B2 (ja) 2016-01-26 2022-07-06 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 抗ｖｗｆ ｄ’ｄ３単一ドメイン抗体及びそれを含むポリペプチド
PT3411478T (pt) 2016-02-01 2022-09-13 Bioverativ Therapeutics Inc Genes do fator viii otimizados
WO2017197048A1 (en) * 2016-05-11 2017-11-16 Amunix Operating Inc. Albumin binding conjugate compositions and methods of making and using same
EP3476937A4 (en) * 2016-06-24 2019-12-04 Mogam Institute for Biomedical Research CHIMERIC PROTEIN WITH FVIII AND VWF FACTORS AND USE THEREOF
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors
KR20190091292A (ko) 2016-12-02 2019-08-05 바이오버라티브 테라퓨틱스 인크. 응고 인자에 대한 면역 내성 유도 방법
GB201707139D0 (en) 2017-05-04 2017-06-21 Imp Innovations Ltd Polypeptides
KR102780287B1 (ko) * 2017-08-09 2025-03-14 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 이의 용도
AU2019215063B2 (en) 2018-02-01 2025-10-16 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing Factor VIII
CA3099049A1 (en) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
CA3105382A1 (en) 2018-08-03 2020-02-06 Sangamo Therapeutics, Inc. Improved clinical parameters by expression of factor viii
BR112021002017A2 (pt) 2018-08-09 2021-05-11 Bioverativ Therapeutics Inc. moléculas de ácido nucleico e usos das mesmas para terapia genética não viral
JP2021535739A (ja) 2018-08-27 2021-12-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 下流精製でのラマン分光法の使用
CN110950964B (zh) * 2018-09-26 2021-06-18 安源医药科技（上海）有限公司 突变型单链人凝血因子viii融合蛋白及其制备方法与用途
JP7672334B2 (ja) * 2018-10-23 2025-05-07 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 第ｖｉｉｉ因子機能を調節するための組成物および方法
KR20210141608A (ko) 2019-03-19 2021-11-23 체에스엘 베링 렝나우 아게 치료요법에서 인자 ix 변이체 및 이의 용도
US10654911B1 (en) * 2019-04-02 2020-05-19 Beijing Neoletix Biological Technology Co., Ltd. Vector co-expressing truncated von Willebrand factor and factor VIII
CN114008069A (zh) 2019-04-17 2022-02-01 科迪亚克生物科学公司 外来体和aav的组合物
EP3736286A1 (en) 2019-05-09 2020-11-11 Biotest AG Single chain factor viii molecule
TW202115127A (zh) 2019-06-19 2021-04-16 美商百歐維拉提夫治療公司 治療血友病及低骨質密度之方法及組成物
JP2022549932A (ja) 2019-09-30 2022-11-29 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
US12173307B2 (en) 2020-06-24 2024-12-24 Bioverativ Therapeutics Inc. Methods for the purification of viral vectors
EP4185469A1 (en) 2020-07-22 2023-05-31 Ricoh Company, Ltd. Ink set, printed matter, printing method, and printing device
AU2022298798A1 (en) 2021-06-23 2024-02-08 Bioverativ Therapeutics Inc. Formulations of factor viii chimeric proteins and uses thereof
JP2024534123A (ja) 2021-08-23 2024-09-18 バイオベラティブ セラピューティクス インコーポレイテッド バキュロウイルス発現システム
AU2022332276A1 (en) 2021-08-23 2024-04-04 Bioverativ Therapeutics Inc. Optimized factor viii genes
KR20240067122A (ko) 2021-09-30 2024-05-16 바이오버라티브 테라퓨틱스 인크. 감소된 면역원성을 갖는 인자 viii 폴리펩타이드를 암호화하는 핵산
CN115873099B (zh) * 2022-12-30 2023-10-20 福因医药科技(武汉)有限公司 一种改造的重组凝血因子viii及其应用
CN116715752B (zh) * 2023-06-16 2024-11-15 苏州诺洁贝生物技术有限公司 凝血因子fviii蛋白变体、表达载体和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013106787A1 (en) 2012-01-12 2013-07-18 Biogen Idec Ma Inc. Chimeric factor viii polypeptides and uses thereof

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
JPH0788399B2 (ja) 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
EP0253870B1 (en) 1986-01-03 1993-03-31 Genetics Institute, Inc. Method for producing factor viii:c-type proteins
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US20060122376A1 (en) 1991-02-07 2006-06-08 Chiron Corporation Protein complexes having factor VIII:C activity and production thereof
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
ES2300113T3 (es) 1996-08-02 2008-06-01 Bristol-Myers Squibb Company Un procedimiento para inhibir toxicidad inducida por inmunoglobulinas que resulta del uso de inmunoglobulinas en terapia y diagnostico in vivo.
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
JP2003526625A (ja) 1999-07-23 2003-09-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 血小板の活性化の調節
EP1983055A1 (en) 2000-04-12 2008-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
JP2001326635A (ja) 2000-05-16 2001-11-22 Matsushita Electric Ind Co Ltd インターネットの課金システム
ES2256234T3 (es) 2000-05-16 2006-07-16 Lipoxen Technologies Limited Derivatizacion de proteinas en solucion acuosa.
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
TW503179B (en) 2001-05-07 2002-09-21 Benq Corp Ink jetting device having bubble valve and the method thereof
JP2003110596A (ja) 2001-09-28 2003-04-11 Hitachi Ltd データ通信サービス提供方法
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2478011C (en) 2002-03-01 2013-05-21 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2003077834A2 (en) 2002-03-15 2003-09-25 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
AU2003275103A1 (en) 2002-09-17 2004-04-08 Diffusion Science, Inc. Electrochemical generation, storage and reaction of hydrogen and oxygen using gas permeable catalyst-coated hollow microspheres
EP2298805A3 (en) 2002-09-27 2011-04-13 Xencor, Inc. Optimized Fc variants and methods for their generation
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
GB2395337B (en) 2002-11-14 2005-12-28 Gary Michael Wilson Warning Unit
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
DK1596887T3 (da) 2003-02-26 2022-06-20 Nektar Therapeutics Polymer-Faktor VIII-konjugat
EP1597279A1 (en) 2003-02-27 2005-11-23 National Research Council Of Canada Peptide inhibitors of thrombin as potent anticoagulants
US7632895B2 (en) 2003-02-28 2009-12-15 Kuraray Co., Ltd. Curable resin composition
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2004239244C1 (en) 2003-05-06 2015-04-23 Bioverativ Therapeutics Inc. Clotting factor-Fc chimeric proteins to treat hemophilia
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
EP1654290B1 (en) 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
JP2007503838A (ja) * 2003-09-05 2007-03-01 ジーティーシー バイオセラピューティクス， インコーポレイティド トランスジェニック動物の乳汁中での融合タンパク質の産生方法
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
CA2552788C (en) 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
JP2008505174A (ja) 2004-07-15 2008-02-21 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
DK1835938T3 (da) 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
GB0516091D0 (en) 2005-08-04 2005-09-14 Haemostatix Ltd Therapeutic agent
BRPI0614761A2 (pt) 2005-08-12 2009-05-19 Human Genome Sciences Inc proteìnas de fusão de albumina
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
AU2007223888A1 (en) 2006-03-06 2007-09-13 Amunix, Inc. Genetic packages and uses thereof
EP1867660A1 (en) 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
KR101641899B1 (ko) 2006-06-14 2016-08-01 체에스엘 베링 게엠베하 혈액 응고 인자를 포함하는 단백질분해적으로 절단가능한 융합 단백질
CA2663352A1 (en) 2006-09-14 2008-03-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
HUE036502T2 (hu) 2006-10-04 2018-07-30 Novo Nordisk As Glicerinhez kapcsolódó pegilált cukrok és glükopeptidek
KR101542752B1 (ko) 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
EP1935430A1 (en) 2006-12-22 2008-06-25 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
EA021222B8 (ru) 2007-06-21 2015-11-30 ИксЭль-ПРОТЕИН ГМБХ Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
EP2185701A4 (en) 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
US8338571B2 (en) 2007-11-01 2012-12-25 University Of Rochester Recombinant factor VIII having increased stability
CA2704234A1 (en) 2007-11-09 2009-05-14 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
SG10201608059VA (en) 2007-12-28 2016-11-29 Baxter Int Recombinant vwf formulations
KR100981092B1 (ko) 2008-02-29 2010-09-08 고려대학교 산학협력단 제8 혈액응고 인자와 폰 빌리 블란트 인자 변이체의 재조합발현 벡터 시스템
US8727449B2 (en) * 2008-03-25 2014-05-20 Johnson Controls Technology Company Vehicular trim applications using film adhesive in lieu of stitching
CN103739712B (zh) * 2008-06-24 2016-10-05 德国杰特贝林生物制品有限公司 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
WO2010060081A1 (en) 2008-11-24 2010-05-27 Bayer Healthcare Llc Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay
US8957021B2 (en) 2009-02-03 2015-02-17 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
CA2756197A1 (en) 2009-03-24 2010-09-30 Bayer Healthcare Llc Factor viii variants and methods of use
US20120121706A1 (en) 2009-04-10 2012-05-17 Tufts Medical Center, Inc. PAR-1 Activation by Metalloproteinase-1 (MMP-1)
PE20121539A1 (es) 2009-06-08 2012-12-06 Amunix Operating Inc Polipeptidos de la hormona de crecimiento y metodos de preparacion
US8450905B2 (en) * 2009-07-23 2013-05-28 New Scale Technologies Methods for controlling velocity of at least partially resonant actuators systems and systems thereof
JP6250282B2 (ja) 2009-08-20 2017-12-20 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性障害の治療および予防的治療における非静脈内投与のためのアルブミン融合凝固因子
CN102741422B (zh) 2009-08-24 2016-06-08 阿穆尼克斯运营公司 凝血因子ⅶ组合物及其制备和使用方法
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
JP5544219B2 (ja) 2009-09-24 2014-07-09 富士フイルム株式会社 内視鏡システム
KR101808751B1 (ko) * 2009-11-13 2017-12-13 그리폴스 테라퓨틱스 인코포레이티드 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
DK2501234T3 (en) 2009-11-20 2017-12-04 Tonix Pharma Holdings Ltd METHODS AND COMPOSITIONS FOR TREATING SYMPTOMS CONNECTED WITH POSTTRAUMATIC LOAD RESPONSE USING CYCLOBENZAPRINE
MX353233B (es) 2009-12-06 2018-01-08 Bioverativ Therapeutics Inc Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.
WO2011084808A2 (en) 2009-12-21 2011-07-14 Amunix Operating Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
CN102770449B (zh) 2010-02-16 2016-02-24 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
EP2977055A1 (en) 2010-02-16 2016-01-27 Novo Nordisk A/S Factor viii fusion protein
US8557961B2 (en) 2010-04-02 2013-10-15 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
AU2011255525B2 (en) 2010-05-20 2015-09-10 Allergan, Inc. Degradable Clostridial toxins
DK2591099T3 (da) 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
EP2591101B1 (en) 2010-07-09 2018-11-07 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
EP2814840B1 (en) * 2012-02-15 2019-11-13 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
JP6383666B2 (ja) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド 組換え第ｖｉｉｉ因子タンパク質
CN104411716B (zh) 2012-04-24 2018-09-07 诺和诺德股份有限公司 适用于治疗血友病的化合物
SG10201701037WA (en) 2012-07-11 2017-03-30 Amunix Operating Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
KR101688986B1 (ko) * 2013-04-19 2016-12-23 주식회사 잉크테크 디스플레이용 투명전극 필름 제조방법 및 디스플레이용 투명전극 필름
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
US10272137B2 (en) * 2013-06-27 2019-04-30 The Board Of Regents Of The University Of Texas System Compositions and methods relating to myomaker-induced muscle cell fusion
HK1223302A1 (zh) 2013-06-28 2017-07-28 Bioverativ Therapeutics Inc. 具有xten的凝血酶可裂解连接子和其用途
HK1223303A1 (zh) 2013-06-28 2017-07-28 Bioverativ Therapeutics Inc. 凝血酶可裂解连接子
HRP20220960T1 (hr) 2014-01-10 2022-10-28 Bioverativ Therapeutics Inc. Kimerni proteini faktora viii i njihova upotreba
EP3588013A1 (de) 2018-06-26 2020-01-01 XelectriX Power GmbH Verfahren zur abgabe von elektrischer energie

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013106787A1 (en) 2012-01-12 2013-07-18 Biogen Idec Ma Inc. Chimeric factor viii polypeptides and uses thereof

Also Published As

Publication number Publication date
FIC20240043I1 (sv) 2024-12-11
SI3091997T1 (sl) 2022-10-28
PH12016501323B1 (en) 2022-04-29
UA120917C2 (uk) 2020-03-10
PH12016501323A1 (en) 2016-08-15
MX389878B (es) 2025-03-19
MY204756A (en) 2024-09-11
NO2024057I1 (no) 2024-12-12
CN106456718B (zh) 2025-11-18
LT4176894T (lt) 2024-06-10
CN116731201A (zh) 2023-09-12
PL3091997T3 (pl) 2023-01-02
IL282168A (en) 2021-05-31
IL246476B (en) 2022-06-01
JP2017503509A (ja) 2017-02-02
JP7104194B2 (ja) 2022-07-20
ES2982051T3 (es) 2024-10-14
EP4176894B1 (en) 2024-02-28
BR112016015512A2 (pt) 2017-10-24
EP3091997A1 (en) 2016-11-16
DK3091997T5 (da) 2024-10-14
US11192936B2 (en) 2021-12-07
BR112016015512B1 (pt) 2023-12-19
AU2015204646B2 (en) 2020-08-27
ES2927475T3 (es) 2022-11-07
CN117106095A (zh) 2023-11-24
RS65533B1 (sr) 2024-06-28
SI4176894T1 (sl) 2024-07-31
PL4176894T3 (pl) 2024-07-22
NZ721544A (en) 2022-10-28
MX2016008958A (es) 2016-09-29
LT3091997T (lt) 2022-08-25
HUS2400043I1 (hu) 2025-01-28
US20250289869A1 (en) 2025-09-18
AU2020277146B2 (en) 2024-05-16
CN116621991A (zh) 2023-08-22
PT3091997T (pt) 2022-09-29
HUE066567T2 (hu) 2024-08-28
EP4176894A1 (en) 2023-05-10
MX2022001134A (es) 2022-07-13
JP2025036503A (ja) 2025-03-14
DK4176894T3 (da) 2024-05-27
AU2015204646A1 (en) 2016-07-14
JP2022118129A (ja) 2022-08-12
SG10201805924PA (en) 2018-08-30
US20220275057A1 (en) 2022-09-01
IL282168B2 (en) 2023-03-01
NL301303I2 (nl) 2025-06-18
LTPA2024536I1 (cg-RX-API-DMAC7.html) 2025-01-10
RS63583B1 (sr) 2022-10-31
EP4389139A2 (en) 2024-06-26
FI4176894T3 (fi) 2024-05-29
HRP20240640T1 (hr) 2024-08-02
IL246476A0 (en) 2016-08-31
CN106456718A (zh) 2017-02-22
AU2024205200A1 (en) 2024-10-03
US20170073393A1 (en) 2017-03-16
CN114736305A (zh) 2022-07-12
MY192481A (en) 2022-08-23
JP2020156520A (ja) 2020-10-01
HUE059820T2 (hu) 2022-12-28
EA201691111A1 (ru) 2017-01-30
JP7612637B2 (ja) 2025-01-14
JP6749836B2 (ja) 2020-09-02
PT4176894T (pt) 2024-05-21
DK3091997T3 (da) 2022-09-26
EP3091997B1 (en) 2022-07-06
BR122023020301A2 (pt) 2023-12-12
JP2021065240A (ja) 2021-04-30
KR20160103136A (ko) 2016-08-31
HRP20220960T1 (hr) 2022-10-28
CN114736305B (zh) 2023-05-05
EP3091997A4 (en) 2017-07-26
FR24C1052I1 (fr) 2025-01-17
JP6906882B2 (ja) 2021-07-21
EP4389139A3 (en) 2024-10-16
WO2015106052A1 (en) 2015-07-16
CN120209161A (zh) 2025-06-27
SG10201913697UA (en) 2020-03-30
IL282168B (en) 2022-11-01
CA2935954A1 (en) 2015-07-16
AU2020277146A1 (en) 2020-12-24
SG11201605242YA (en) 2016-07-28

Similar Documents

Publication Publication Date Title
KR102409250B1 (ko) 인자 viii 키메라 단백질 및 이들의 용도
AU2022252703B2 (en) Factor VIII complex with XTEN and von Willebrand factor protein, and uses thereof
KR102212098B1 (ko) 키메라 인자 viii 폴리펩티드들과 이의 용도
AU2017214378B2 (en) Optimized Factor VIII genes
KR20210020030A (ko) A형 혈우병의 치료 방법
RS61387B2 (sr) Gen optimizovanog faktora viii
CA2935954C (en) Factor viii chimeric proteins and uses thereof
CA2878679C (en) Factor viii complex with xten and von willebrand factor protein, and uses thereof
BR122023020301B1 (pt) Uso de uma proteína quimérica compreendendo uma proteína fviii
EA042955B1 (ru) Способ лечения заболевания или состояния, связанного с кровотечениями, с использованием комплекса фактора viii с xten и белком фактора фон виллебранда и его применение

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160809

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20180517

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200108

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210830

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220504

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220610

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220610

End annual number: 3

Start annual number: 1

PG1601 Publication of registration